Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2018-05-04 Proxy Solicitation & In…
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon ASA - Flagging av fullmakter
Proxy Solicitation & Information Statement Classification · 99% confidence The document is titled "Biotec Pharmacon ASA - Flagging av fullmakter" (Flagging of proxies/powers of attorney). It details the number of shares represented by proxies received by the CEO for the upcoming ordinary general meeting on May 7, 2018. This content directly relates to the preparation and status of voting rights and representation for a general meeting. This aligns best with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA), as it is a pre-meeting announcement detailing the proxies received which determine voting power, even though it is not the final result itself. Given the context of a general meeting and proxy handling, DVA is the most specific fit among the options, although it is a pre-result announcement. Since it is not a presentation (AGM-R) or a proxy solicitation document (PSI), DVA is chosen as the closest fit for voting-related administrative updates.
2018-05-04 Norwegian
Biotec Pharmacon: Results for Q1 2018
Earnings Release Classification · 98% confidence The document explicitly states "Results for Q1 2018" and provides key financial metrics (sales, EBITDA) for the first quarter. It also mentions that "The complete interim report for Q1 2018 is enclosed." This structure—a brief summary of quarterly results followed by a reference to the full report—is characteristic of an Earnings Release (ER). Although it mentions an enclosed interim report, the provided text itself is the initial announcement summarizing the period's performance, not the comprehensive report (which would be classified as IR). The document length is short (2560 chars), suggesting it is the release announcement rather than the full report. Q1 2018
2018-04-26 Norwegian
Biotec Pharmacon: Results for Q1 2018
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Biotec Pharmacon ASA for Q1 2018. It contains detailed financial statements (Sales, EBITDA, EBIT, Cash Flow), business segment analysis (Beta-glucans, Woulgan, ArcticZymes), and management commentary on performance and outlook. It is not a mere announcement or certification, but the full interim report itself. Q1 2018
2018-04-26 Norwegian
Biotec Pharmacon: Q1 2018 Presentation
Investor Presentation Classification · 98% confidence The document is explicitly titled "Q1 2018 Presentation" and contains detailed slides covering business highlights, segment performance (Beta-glucans and Enzymes), clinical trial updates, and a dedicated section titled "Q1 Financials" which includes segment sales breakdowns, EBITDA comparisons, and cash flow details for the first quarter. This structure is characteristic of an Investor Presentation (IP) used to discuss recent quarterly performance, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). Since it is a presentation format detailing financial results and outlook, Investor Presentation (IP) is the most appropriate classification.
2018-04-26 English
Biotec Pharmacon: Results for Q1 2018
Earnings Release Classification · 100% confidence The document explicitly states "Biotec Pharmacon: Results for Q1 2018" and provides key financial metrics (sales, EBITDA) and operational highlights for the first quarter. It concludes by stating, "The complete interim report for Q1 2018 is enclosed." This structure—a summary of quarterly results followed by a reference to the full report—is characteristic of an Earnings Release (ER). Although it mentions the full report is enclosed, the primary content provided is the summary of results, not just an announcement of publication (which would be RPA/RNS). Since it covers a period shorter than a year (Q1), it fits the definition of an Interim/Quarterly Report summary, which aligns best with the Earnings Release (ER) code, as it is the initial announcement of period results. Q1 2018
2018-04-26 English
Biotec Pharmacon: Q1 2018 Presentation
Report Publication Announcement Classification · 98% confidence The document text is very short (480 characters) and explicitly states that the company is presenting its 'interim report for the first quarter of 2018' and that the 'presentation [is] attached' and 'also available as a webcast'. This structure—announcing the release of a report/presentation and providing access details—fits the definition of a Report Publication Announcement (RPA) rather than the full Interim Report (IR) itself. The content is an announcement about the Q1 2018 presentation.
2018-04-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.